Fig. 2From: Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patientsCost effectiveness plane—DTG + TDF/3TC vs EFV + TDF/3TC (treatment-naïve) and DTG + TDF/3TC vs LPV/r + TDF/3TC (first-line failures)Back to article page